Dube Eric M 4
4 · Travere Therapeutics, Inc. · Filed Jan 27, 2026
Research Summary
AI-generated summary of this filing
Travere (TVTX) CEO Eric Dube Exercises Options, Sells 60,000 Shares
What Happened
Eric M. Dube, CEO of Travere Therapeutics (TVTX), exercised a total of 60,000 stock options (coded M) and sold the 60,000 resulting shares in open-market transactions (coded S). On Jan 23, 2026 he exercised 8,135 options at $15.46/share (cost $125,767) and sold those 8,135 shares at about $30.01/share for $244,153. On Jan 27, 2026 he exercised 51,865 options at $15.46/share (cost $801,833) and sold those 51,865 shares at about $30.10/share for $1,560,981. Total cash paid to exercise: $927,600; total gross proceeds from sales: approximately $1,805,134. The filing also includes standard derivative-conversion reporting (zero-dollar derivative dispositions) reflecting the option-to-share conversions.
Key Details
- Transaction dates & prices:
- 2026-01-23: Exercised 8,135 options @ $15.46 (acquired) and sold 8,135 shares @ ~$30.01 (proceeds $244,153).
- 2026-01-27: Exercised 51,865 options @ $15.46 (acquired) and sold 51,865 shares @ ~$30.10 (proceeds $1,560,981).
- Totals: 60,000 options exercised, $927,600 paid to exercise, ~ $1.81M gross sale proceeds.
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Notable footnotes:
- Sale(s) were made pursuant to a written 10b5-1 trading plan adopted June 16, 2025 (F1).
- Weighted-average sale-price details and price ranges provided in the filing (F2, F3).
- Reported options were fully vested and exercisable (F4).
- Filing timeliness: Transactions occurred Jan 23 & Jan 27, 2026; the Form 4 was filed Jan 27, 2026 and was not reported as late.
Context
- This is an exercise of vested options followed by immediate open-market sales of the resulting shares (commonly a cashless exercise/sell). The presence of a 10b5-1 plan indicates the sales were preplanned and executed under that program. As always, sales by insiders can be routine (e.g., to cover exercise cost/taxes) and do not, by themselves, indicate the insider’s view of the company’s prospects.
Insider Transaction Report
- Exercise/Conversion
Common Stock
2026-01-23$15.46/sh+8,135$125,767→ 427,308 total - Sale
Common Stock
[F1][F2]2026-01-23$30.01/sh−8,135$244,153→ 419,173 total - Exercise/Conversion
Common Stock
2026-01-27$15.46/sh+51,865$801,833→ 471,038 total - Sale
Common Stock
[F1][F3]2026-01-27$30.10/sh−51,865$1,560,981→ 419,173 total - Exercise/Conversion
Employee stock option (right to buy)
[F4]2026-01-23−8,135→ 171,865 totalExercise: $15.46Exp: 2030-01-31→ Common Stock (8,135 underlying) - Exercise/Conversion
Employee stock option (right to buy)
[F4]2026-01-27−51,865→ 120,000 totalExercise: $15.46Exp: 2030-01-31→ Common Stock (51,865 underlying)
Footnotes (4)
- [F1]This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- [F2]The weighted average sale price for the transaction reported was $30.0127, and the range of prices were between $30.00 and $30.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- [F3]The weighted average sale price for the transaction reported was $30.097, and the range of prices were between $30.00 and $30.49. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- [F4]The stock option is fully vested and exercisable.